Risk of Developing Antibodies to Heparin-PF4 After Heart Surgery
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
Heparin is a drug that is widely used to prevent and treat blood clotting. Individuals
undergoing cardiopulmonary bypass surgery are administered high doses of heparin, and some of
them develop antibodies to the drug. This immune response can lead to the formation of blood
clots, setting the stage for a potential heart attack or stroke. The purpose of this study is
to evaluate how often an immune response to heparin leads to the formation of blood clots in
individuals who have had heart surgery.